EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides

Aurélie Goyenvalle iD, Cecilia Jimenez-Mallebrera, Willeke van Roon iD, Sabine Sewing, Arthur M Krieg, Virginia Arechavala-Gomeza iD, Patrik Andersson iD

Nucleic Acid Therapeutics · 01.02.2023 · 33 (1) · 1-16

DOI: 10.1089/nat.2022.0061 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nucleic Acid Therapeutics, online erschienen am 28.12.2022. Verfasst von Aurélie Goyenvalle und 6 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris-Saclay, UVSQ, Inserm, END-ICAP, Versailles, France. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, Oligonucleotides. Die Arbeit wurde bisher 98-mal zitiert (Crossref) und nennt 147 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The nucleic acid therapeutics field has made tremendous progress in the past decades. Continuous advances in chemistry and design have led to many successful clinical applications, eliciting even more interest from researchers including both academic groups and drug development companies. Many preclinical studies in the field focus on improving the delivery of antisense oligonucleotide drugs (ONDs) and/or assessing their efficacy in target tissues, often neglecting the evaluation of toxicity, at least in early phases of development. A series of consensus recommendations regarding regulatory considerations and expectations have been generated by the Oligonucleotide Safety Working Group and the Japanese Research Working Group for the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use S6 and Related Issues (WGS6) in several white papers. However, safety aspects should also be kept in sight in earlier phases while screening and designing OND to avoid subsequent failure in the development phase. Experts and members of the network “DARTER,” a COST Action funded by the Cooperation in Science and Technology of the EU, have utilized their collective experience working with OND, as well as their insights into OND-mediated toxicities, to generate a series of consensus recommendations to assess OND toxicity in early stages of preclinical research. In the past few years, several publications have described predictive assays, which can be used to assess OND-mediated toxicity in vitro or ex vivo to filter out potential toxic candidates before moving to in vivo phases of preclinical development, that is, animal toxicity studies. These assays also have the potential to provide translational insight since they allow a safety evaluation in human in vitro systems. Yet, small preliminary in vivo studies should also be considered to complement this early assessment. In this study, we summarize the state of the art and provide guidelines and recommendations on the different tests available for these early stage preclinical assessments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oligonucleotides, AntisenseOligonucleotidesAnimalsHumansPharmaceutical PreparationsDrug Evaluation, Preclinical

Stichwörter der Autor:innen

antisense oligonucleotidesearly preclinical safety assessmentpredictive assaystoxicity

Substanzen

Oligonucleotides, AntisenseOligonucleotidesPharmaceutical Preparations

Autor:innen und Institutionen

  • Université Paris-Saclay, UVSQ, Inserm, END-ICAP, Versailles, France.
  • Laboratorio de Investigación Aplicada en Enfermedades Neuromusculares, Unidad de Patología Neuromuscular, Servicio de Neuropediatría, Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain.
  • Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
  • Departamento de Genética, Microbiología y Estadística, Universitat de Barcelona, Barcelona, Spain.
  • Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.
  • Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.

ORCID-Profile: Aurélie Goyenvalle, Willeke van Roon, Virginia Arechavala-Gomeza, Patrik Andersson

Zitieren

APA

Goyenvalle, A., Jimenez-Mallebrera, C., van Roon, W., Sewing, S., Krieg, A. M., Arechavala-Gomeza, V., & Andersson, P. (2023). Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides. Nucleic Acid Therapeutics, 33(1), 1-16. https://doi.org/10.1089/nat.2022.0061

Vancouver

Goyenvalle A, Jimenez-Mallebrera C, van Roon W, Sewing S, Krieg AM, Arechavala-Gomeza V, et al. Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides. Nucleic Acid Therapeutics. 2023;33(1):1-16. doi:10.1089/nat.2022.0061

BibTeX
@article{Goyenvalle2023,
  author = {Goyenvalle, Aurélie and Jimenez-Mallebrera, Cecilia and van Roon, Willeke and Sewing, Sabine and Krieg, Arthur M and Arechavala-Gomeza, Virginia and Andersson, Patrik},
  title = {Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides},
  journal = {Nucleic Acid Therapeutics},
  year = {2023},
  volume = {33},
  number = {1},
  pages = {1--16},
  doi = {10.1089/nat.2022.0061}
}
Kostenlos starten →